These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 16725322)

  • 1. Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors.
    Varaprasad CV; Barawkar D; El Abdellaoui H; Chakravarty S; Allan M; Chen H; Zhang W; Wu JZ; Tam R; Hamatake R; Lang S; Hong Z
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3975-80. PubMed ID: 16725322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.
    El Abdellaoui H; Varaprasad CV; Barawkar D; Chakravarty S; Maderna A; Tam R; Chen H; Allan M; Wu JZ; Appleby T; Yan S; Zhang W; Lang S; Yao N; Hamatake R; Hong Z
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5561-6. PubMed ID: 16934458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
    VanScyoc WS; Holdgate GA; Sullivan JE; Ward WH
    Biochemistry; 2008 Apr; 47(17):5017-27. PubMed ID: 18393446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
    Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1195-8. PubMed ID: 19124243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation.
    Tegley CM; Viswanadhan VN; Biswas K; Frohn MJ; Peterkin TA; Chang C; Bürli RW; Dao JH; Veith H; Rogers N; Yoder SC; Biddlecome G; Tagari P; Allen JR; Hungate RW
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3925-8. PubMed ID: 18579373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
    Uto Y; Ogata T; Harada J; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Abe M; Kurikawa N; Kawamura S; Yamato M; Osumi J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4151-8. PubMed ID: 19540759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.
    Desar IM; Bovenschen HJ; Timmer-Bonte AJ; Cantarini MV; Van Der Graaf WT; Van Rossum MM; Van Herpen CM
    Acta Oncol; 2010; 49(1):110-3. PubMed ID: 19634052
    [No Abstract]   [Full Text] [Related]  

  • 11. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
    Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
    Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
    Spicer JA; Rewcastle GW; Kaufman MD; Black SL; Plummer MS; Denny WA; Quin J; Shahripour AB; Barrett SD; Whitehead CE; Milbank JB; Ohren JF; Gowan RC; Omer C; Camp HS; Esmaeil N; Moore K; Sebolt-Leopold JS; Pryzbranowski S; Merriman RL; Ortwine DF; Warmus JS; Flamme CM; Pavlovsky AG; Tecle H
    J Med Chem; 2007 Oct; 50(21):5090-102. PubMed ID: 17880056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
    Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines.
    Douty B; Wayland B; Ala PJ; Bower MJ; Pruitt J; Bostrom L; Wei M; Klabe R; Gonneville L; Wynn R; Burn TC; Liu PC; Combs AP; Yue EW
    Bioorg Med Chem Lett; 2008 Jan; 18(1):66-71. PubMed ID: 18037290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
    Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
    Richards S; Sorensen B; Jae HS; Winn M; Chen Y; Wang J; Fung S; Monzon K; Frevert EU; Jacobson P; Sham H; Link JT
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6241-5. PubMed ID: 17000111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
    Rexer BN; Ghosh R; Arteaga CL
    Clin Cancer Res; 2009 Jul; 15(14):4518-20. PubMed ID: 19584146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.
    Ni S; Yuan Y; Huang J; Mao X; Lv M; Zhu J; Shen X; Pei J; Lai L; Jiang H; Li J
    J Med Chem; 2009 Sep; 52(17):5295-8. PubMed ID: 19691347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.